Ocata Therapeutics, Inc.
Investor & Media
Press Releases
Ocata Therapeutics to Host Conference Call and Webcast to Provide Corporate Update for the First Quarter of 2015
Call Scheduled for Thursday, May 7, 2015 at 4:30 P.M.
Related Links
PDF
Release PDF
MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced today that it will host a conference call on Thursday, May 7, 2015 at 4:30 p.m. EDT, during which it will provide a corporate update for the first quarter of 2015.
Interested parties may access the call live by dialing (800) 753-0487 (US) or (913) 312-0713 (international) and using conference ID 3671771.
A live audio webcast of the presentation will be available via the “Investor Relations” page of the Ocata website, www.ocata.com. A replay of the webcast will be archived on Ocata’s website for 90 days.
About Ocata Therapeutics, Inc.
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of regenerative ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs. For more information, visit www.ocata.com.
About Age-related Macular Degeneration
Age-related macular degeneration is the leading cause of vision loss in people over the age of 50. Every year in the USA there are 1.8 million patients newly diagnosed with dry AMD which occurs when light-sensitive photoreceptor cells in the macula, located in the center of the retina, slowly break down, causing vision loss as a result. Photoreceptor breakdown is a consequence of loss or damage to the RPE layer. As the disease progresses, patients may have difficulty reading and recognizing faces. There is currently no proven medical therapy for dry AMD and the projected number of people worldwide with age-related macular degeneration in 2020 is 196 million, increasing to 288 million in 2040 underscoring the urgent need for new treatments.
About Stargardt’s Disease
Stargardt’s macular degeneration is a form of juvenile macular degeneration that affects vision in children and young adults between the ages of six and 20, with a prevalence of approximately one in 10,000 people in the United States. It is an orphan disease and loss of vision is an inevitable aspect of SMD, with more than half of the patients experiencing vision loss in the range of 20/200-20/400. Like dry AMD, it occurs as a result of damage to the RPE layer and there are no treatments currently approved to prevent or slow the vision loss associated with SMD.
Investors:
Westwicke Partners
John Woolford, 443-213-0506
john.woolford@westwicke.com
or
Press:
Russo Partners
David Schull, 858-717-2310
david.schull@russopartnersllc.com
Source: Ocata Therapeutics, Inc.
Released May 4, 2015
Overview
Press Releases
Events & Presentations
Financials & Filings
Stock Data
Corporate Governance
IR Contacts
Email Alerts
Snapshot
NASDAQ: OCAT
Price:
7.25
Change:
-0.13
Day High:
7.48
Day Low:
7.18
Volume:
129,559
05/01/2015 03:59 PM EDT
View Detailed Stock Data »
Investor Relations
Westwicke Partners
John Woolford
T: (443) 213-0506
john.woolford@westwicke.com
©2014 Ocata Therapeutics, Inc. All rights reserved.
Legal Disclaimer
About Us
Overview
Leadership
The Meaning of Ocata
Careers
Contact Us
Our Approach
A New Pillar of Medicine
Market Insights
Our Regenerative Approach
Enhancing Quality of Life
World-Class Scientists
Research & Development
Pipeline Overview
Regenerative Ophthalmology
Other Regenerative Medicine Programs
Scientific Papers
Clinical Trials
Ongoing Clinical Trials
Disease Information
Investor & Media
Overview
Press Releases
Events & Presentations
Financials & Filing
Stock Data
Corporate Governance
IR Contacts
Email Alerts
Snapshot
Contact
Site Design: Monderer Design
AI
